Kamarck Michael E.
Known title: DirectorCIK: 0001450730
Associated companies
Transaction History
| PCVX | ▲ Buy | Grant | 2,500 | $0 | 6/13/2023 | View on chart |
| PCVX | ▲ Buy | Grant | 3,125 | $0 | 6/1/2022 | View on chart |
| PCVX | ▲ Buy | Grant | 2,500 | $0 | 6/13/2023 | View on chart |
| PCVX | ▲ Buy | Grant | 3,125 | $0 | 6/1/2022 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Vaxcyte VAX-31 clears Phase III OPUS-1 trial endpoints
Vaxcyte announced that its VAX-31 vaccine met all primary endpoints in the pivotal Phase III OPUS-1 trial. This positive data point positions the company for additional readouts expected in the first half of 2027. The stock is currently trading near its 52-week high, reflecting strong market interest in the clinical progress.
Vaxcyte VAX-31 clears Phase III OPUS-1 trial endpoints. Vaxcyte announced that its VAX-31 vaccine met all primary endpoints in the pivotal Phase III OPUS-1 trial. This positive data point positions the company for additional readouts expected in the first half of 2027. The stock is currently trading near its 52-week high, reflecting strong market interest in the clinical progress.